Resmed - First Linde Then CNBC And Jim Cramer
You will recall two days ago the market noise that Resmed was about to be picked up by German Linde. We blogged about it here.
Now CNBC’s Jim Cramer talked about them benefiting from the potential reversal or low impact of competitive bidding. (I don’t think competitive bidding will be substantially reversed just to be clear.
Jim Cramer goes on to issue a potential target price of $53 which is a cool 30% premium.
0 comments
Kick things off by filling out the form below.
Leave a Comment